Table 3 Logistic regression analysis evaluating the association between MASLD and CSF in adolescents with SLD.

From: Prevalence of steatotic liver disease (MASLD, MetALD, ALD) and clinically significant fibrosis in US adolescents

 

CSF

OR

95% CI

P-value

SLD-MASLD (%)

 SLD without MASLD

1.0

 SLD with MASLD

1.11

0.31–4.00

0.8736

 Female sex (%)

0.63

0.36–1.09

0.1005

 Age (years, per unit increase)

1.09

0.87–1.35

0.4518

Race-ethnicity (%)

 Non-Hispanic White

1.0

 Non-Hispanic Black

3.27

1.61–6.65

0.0011

 Hispanic

0.61

0.13–2.81

0.5283

 Other

1.25

0.59–2.65

0.5644

  1. MASLD, metabolic dysfunction-associated steatotic liver disease; CSF, clinically significant fibrosis; LSM, liver stiffness measurement; OR, odds ratio; CI, confidence interval. Age, sex and race/ethnicity were adjusted.
Back to article page